Publications

STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastoma

Download PDF
Resource: STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastoma

.

Related Articles

Targeted removal of macrophage-secreted interleukin-1 receptor antagonist protects against lethal Candida albicans sepsis

Link
Microglial Fructose Metabolism Is Essential for Glioblastoma Growth

Link